{"id":"NCT02750592","sponsor":"Novartis Pharmaceuticals","briefTitle":"Study of Efficacy and Safety of Secukinumab in Japanese Patients With Active Ankylosing Spondylitis","officialTitle":"An Open-label, Phase III, Study of Subcutaneous Secukinumab to Assess Efficacy, Safety and Tolerability at up to 52 Weeks in Japanese Patients With Active Ankylosing Spondylitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-03-22","primaryCompletion":"2017-07-05","completion":"2018-05-16","firstPosted":"2016-04-25","resultsPosted":"2019-09-09","lastUpdate":"2019-09-09"},"enrollment":30,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Ankylosing Spondylitis"],"interventions":[{"type":"DRUG","name":"Secukinumab 150 mg provided in 1.0 mL pre-filled syringes (PFSs) for sc injection.","otherNames":[]}],"arms":[{"label":"secukinumab 150mg","type":"EXPERIMENTAL"}],"summary":"The purpose of this study was to assess the clinical efficacy, safety and tolerability of secukinumab subcutaneous injections up to 52 weeks in Japanese patients with active AS despite current or previous non-steroidal anti-inflammatory drugs (NSAIDs) and/or anti-tumor necrosis factor (TNF) Î± therapy. Efficacy and safety data were used to support the registration of secukinumab in Japan for the treatment of active AS.","primaryOutcome":{"measure":"Assessment of SpondyloArthritis International Society 20 Response (ASAS20)","timeFrame":"week 16","effectByArm":[{"arm":"Secukinumab 150mg","deltaMin":21,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":10,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":30},"commonTop":["Nasopharyngitis","Stomatitis","Influenza","Gastroenteritis","Leukopenia"]}}